Inogen, Inc - Common Stock (INGN)
8.5100
-0.0100 (-0.12%)
NASDAQ · Last Trade: Oct 17th, 1:12 AM EDT
Detailed Quote
Previous Close | 8.520 |
---|---|
Open | 8.560 |
Bid | 8.510 |
Ask | 8.530 |
Day's Range | 8.470 - 8.750 |
52 Week Range | 5.700 - 12.91 |
Volume | 126,406 |
Market Cap | 196.76M |
PE Ratio (TTM) | -8.028 |
EPS (TTM) | -1.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 180,305 |
Chart
About Inogen, Inc - Common Stock (INGN)
Inogen Inc is a medical technology company that specializes in the development, manufacturing, and marketing of innovative portable oxygen concentrators designed to assist individuals with chronic respiratory conditions. By providing patients with greater mobility and independence, Inogen’s products enable users to maintain an active lifestyle while managing their oxygen needs. The company is committed to enhancing the quality of life for patients by offering lightweight, user-friendly devices that can be used both at home and on the go, making oxygen therapy more accessible and convenient. Read More
News & Press Releases
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET.
By Inogen, Inc. · Via Business Wire · October 15, 2025
Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms.
By Inogen, Inc. · Via Business Wire · September 25, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025.
By Inogen, Inc. · Via Business Wire · August 7, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
By Inogen, Inc. · Via Business Wire · July 17, 2025
Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company’s line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels.
By Inogen, Inc. · Via Business Wire · June 23, 2025
Via Benzinga · June 10, 2025
Needham's Mike Matson upgrades Inogen to Buy, citing turnaround progress, margin gains, and path to EBITDA breakeven by 2025.
Via Benzinga · May 22, 2025
Via Benzinga · May 22, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025.
By Inogen, Inc. · Via Business Wire · May 7, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
By Inogen, Inc. · Via Business Wire · April 16, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference.
By Inogen, Inc. · Via Business Wire · March 20, 2025

Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks.
Via Benzinga · February 26, 2025

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024.
By Inogen, Inc. · Via Business Wire · February 25, 2025

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen’s Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025.
By Inogen, Inc. · Via Business Wire · February 3, 2025

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ, “Yuwell”), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products.
By Inogen, Inc. · Via Business Wire · January 26, 2025

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024.
By Inogen, Inc. · Via Business Wire · January 13, 2025

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company’s ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S.
By Inogen, Inc. · Via Business Wire · December 30, 2024

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024.
By Inogen, Inc. · Via Business Wire · November 7, 2024

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences:
By Inogen, Inc. · Via Business Wire · November 4, 2024

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
By Inogen, Inc. · Via Business Wire · October 17, 2024

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has commenced the U.S. market release of the Inogen® Rove 4™ Portable Oxygen Concentrator.
By Inogen, Inc. · Via Business Wire · October 8, 2024

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer.
By Inogen, Inc. · Via Business Wire · September 5, 2024